SpringWorks Therapeutics Inc (SWTX) USD0.0001

Sell:$41.87Buy:$41.94$2.20 (4.99%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$41.87
Buy:$41.94
Change:$2.20 (4.99%)
Market closed | Prices delayed by at least 15 minutes
Sell:$41.87
Buy:$41.94
Change:$2.20 (4.99%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.

Key people

Saqib Islam
Chief Executive Officer, Director
Francis Perier
Chief Financial Officer
Badreddin Edris
Chief Operating Officer
Daniel Pichl
Chief People Officer
Tai-an Lin
Chief Scientific Officer
Herschel S. Weinstein
General Counsel, Secretary
Bhavesh Ashar
Chief Commercial Officer
James Cassidy
Chief Medical Officer
Daniel S. Lynch
Independent Chairman of the Board
Carlos Alban
Independent Director
Alan Fuhrman
Independent Director
Julie Hambleton
Independent Director
Martin W. Mackay
Independent Director
Click to see more

Key facts

  • EPIC
    SWTX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US85205L1070
  • Market cap
    $3.31bn
  • Employees
    368
  • Shares in issue
    75.28m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.